SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

NCT04269642 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the drug SR-Exenatide (PT320) is safe and effective for people in the early stages of Parkinson's disease.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 99 people Planned (estimated).

Who can join Ages 40–75 · all sexes

Timeline Started 2020-03 · est. completion 2021-12

Where 5 sites · South Korea

What this study is testing ClinicalTrials.gov NCT04269642 ↗

Description as written by the study sponsor.

This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320, Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).

Treatments tested

PT320 2.0mg Placebo Drug

PT320 2.0mg Placebo
PT320 2.0 mg Drug

Exenatide slowly released formulation
PT320 2.5 mg Drug

Exenatide slowly released formulation

Main thing measured	Change of MDS-UPDRS part 3 score
Sponsor	Peptron, Inc.
Conditions studied	Early Parkinson's Disease
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04269642 ↗